Back to top

Analyst Blog

Zacks Equity Research

Sales Slip at McKesson

MCK

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

McKesson Corporation’s (MCK - Analyst Report) second quarter fiscal 2013 (ended September 30, 2012) adjusted earnings of $1.92 per share surpassed the Zacks Consensus Estimate of $1.76 per share. Also, the reported quarter’s adjusted earnings spiked 18% from the year-ago period. Earnings benefited from a lower share count.

Revenues declined 1% to $29.9 billion. Revenues were short of the Zacks Consensus Estimate of $30.9 billion.

Quarter in Detail

McKesson operates through two segments: Distribution Solutions and Technology Solutions.

Revenues at the Distribution Solutions segment decreased 1% to $29 billion in the reported quarter. The decline was attributable to lower sales in the US pharmaceutical distribution unit.

Revenues from the US pharmaceutical distribution business came in at $25.7 billion, down 1%. The decline was due to brand-to-generic conversions and one less sales day.    

Canadian revenue decreased 5% to $2.4 billion. The decrease was attributable to unfavorable foreign exchange movements. Revenues from Medical-Surgical distribution and services came in flat at $873 million. Sales of the sub-group were impacted by fewer sales days in the quarter.

Revenues at the Technology Solutions segment came in flat at $824 million. Operating expenses climbed 1.9% in the reported quarter to $1.1 billion.

Fiscal 2013 Outlook

The company tweaked its adjusted earnings outlook for fiscal 2013. McKesson expects earnings (excluding special items) in the range of $7.15-$7.35 per share (previous projection: $7.05 - $7.35 share). The Zacks Consensus Estimate for fiscal 2013 currently stands at $7.26 per share.

McKesson to Buy PSS World

In a bid to expand its product portfolio, McKesson inked a deal to buy PSS World Medical, Inc. for $29.00 per share in cash. The total value of the deal, in which McKesson will assume PSS World Medical’s debt, is estimated at approximately $2.1 billion. McKesson expects to generate more than $100 million in annual savings (pre-tax) by the fourth year after the closure of the deal.

Neutral on McKesson

We currently have a Neutral recommendation on McKesson. The stock carries a Zacks #3 Rank (Hold rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LAKE SHORE G LSG 0.77 +6.05%
QUESTCOR PHA QCOR 80.07 +2.47%
VIPSHOP HOLD VIPS 156.35 +1.82%
ENLINK MIDST ENLC 36.29 +1.60%
BNC BANCORP BNCN 17.33 +1.58%